KR100632908B1 - 호르몬-의존성 질병의 예방 및 치료를 위한항프로게스틴의 용도 - Google Patents

호르몬-의존성 질병의 예방 및 치료를 위한항프로게스틴의 용도 Download PDF

Info

Publication number
KR100632908B1
KR100632908B1 KR1020037005359A KR20037005359A KR100632908B1 KR 100632908 B1 KR100632908 B1 KR 100632908B1 KR 1020037005359 A KR1020037005359 A KR 1020037005359A KR 20037005359 A KR20037005359 A KR 20037005359A KR 100632908 B1 KR100632908 B1 KR 100632908B1
Authority
KR
South Korea
Prior art keywords
antiprogestin
treatment
breast cancer
hormone
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037005359A
Other languages
English (en)
Korean (ko)
Other versions
KR20030044007A (ko
Inventor
옌스 호프만
로제마리 리흐트너
게르하르트 지마이스터
마르틴 슈나이더
울리케 푸르만
Original Assignee
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 악티엔게젤샤프트 filed Critical 쉐링 악티엔게젤샤프트
Publication of KR20030044007A publication Critical patent/KR20030044007A/ko
Application granted granted Critical
Publication of KR100632908B1 publication Critical patent/KR100632908B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020037005359A 2000-10-18 2001-10-17 호르몬-의존성 질병의 예방 및 치료를 위한항프로게스틴의 용도 Expired - Fee Related KR100632908B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24099800P 2000-10-18 2000-10-18
EP00250341.5 2000-10-18
EP00250341 2000-10-18
US60/240,998 2000-10-18
PCT/EP2001/012005 WO2002032430A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Publications (2)

Publication Number Publication Date
KR20030044007A KR20030044007A (ko) 2003-06-02
KR100632908B1 true KR100632908B1 (ko) 2006-10-13

Family

ID=26072951

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037005359A Expired - Fee Related KR100632908B1 (ko) 2000-10-18 2001-10-17 호르몬-의존성 질병의 예방 및 치료를 위한항프로게스틴의 용도

Country Status (26)

Country Link
US (1) US7378406B2 (https=)
EP (1) EP1328276B1 (https=)
JP (2) JP2004511522A (https=)
KR (1) KR100632908B1 (https=)
CN (1) CN1512886A (https=)
AT (1) ATE310522T1 (https=)
AU (2) AU1824302A (https=)
BG (1) BG107743A (https=)
BR (1) BR0114665A (https=)
CA (1) CA2423017C (https=)
CY (1) CY1104981T1 (https=)
CZ (1) CZ299942B6 (https=)
DE (1) DE60115274T2 (https=)
DK (1) DK1328276T3 (https=)
EE (1) EE05259B1 (https=)
ES (1) ES2253443T3 (https=)
HR (1) HRP20030387A2 (https=)
HU (1) HUP0301460A3 (https=)
IL (2) IL154975A0 (https=)
MX (1) MXPA03002954A (https=)
NO (1) NO20031740L (https=)
NZ (1) NZ538346A (https=)
PL (1) PL360151A1 (https=)
SI (1) SI1328276T1 (https=)
SK (1) SK287124B6 (https=)
WO (1) WO2002032430A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US9517240B2 (en) * 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP3865502A1 (en) * 2010-03-22 2021-08-18 Allergan Pharmaceuticals International Limited Compositions and methods for non-toxic delivery of cdb-2914
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
ES2688821T3 (es) 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
JP2010077158A (ja) 2010-04-08
IL154975A (en) 2007-05-15
EP1328276A1 (en) 2003-07-23
SK287124B6 (sk) 2009-12-07
BR0114665A (pt) 2004-01-13
CA2423017A1 (en) 2002-04-25
SI1328276T1 (sl) 2006-04-30
IL154975A0 (en) 2003-10-31
CZ299942B6 (cs) 2008-12-29
JP2004511522A (ja) 2004-04-15
ATE310522T1 (de) 2005-12-15
EE05259B1 (et) 2010-02-15
KR20030044007A (ko) 2003-06-02
HRP20030387A2 (en) 2005-04-30
DK1328276T3 (da) 2006-04-03
HUP0301460A2 (hu) 2003-10-28
CY1104981T1 (el) 2010-03-03
CN1512886A (zh) 2004-07-14
NO20031740D0 (no) 2003-04-15
CA2423017C (en) 2009-01-06
DE60115274T2 (de) 2006-07-27
US20040048841A1 (en) 2004-03-11
AU1824302A (en) 2002-04-29
PL360151A1 (en) 2004-09-06
AU2002218243B2 (en) 2006-07-13
MXPA03002954A (es) 2003-08-07
EP1328276B1 (en) 2005-11-23
HUP0301460A3 (en) 2010-01-28
NZ538346A (en) 2007-03-30
US7378406B2 (en) 2008-05-27
NO20031740L (no) 2003-06-17
EE200300155A (et) 2003-08-15
BG107743A (bg) 2004-01-30
DE60115274D1 (de) 2005-12-29
SK4742003A3 (en) 2004-09-08
ES2253443T3 (es) 2006-06-01
WO2002032430A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
KR100632908B1 (ko) 호르몬-의존성 질병의 예방 및 치료를 위한항프로게스틴의 용도
AU2002218243A1 (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
KR100668024B1 (ko) 유방암, 난소암, 자궁내막암, 골수종 및 수막종 치료용 약제를 제조하기 위한 11베타-(4-아세틸페닐)-17베타-히드록시-17알파-(1,1,2,2,2-펜타플루오로에틸)에스트라-4,9-디엔-3-온의 용도
KR20060005412A (ko) 호르몬-의존성 질환의 예방 및 치료를 위한 항프로게스틴및 순수한 항에스트로겐을 포함하는 조성물
AU2002223619A1 (en) Use of antiprogestins for the induction of apoptosis in a cell
US20040072811A1 (en) Use of antiprogestins for the induction of apoptosis in a cell
ZA200303793B (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases.
JP2010524998A (ja) Ｂｒｃａ介在性疾患における使用のための非ステロイド系抗エストロゲンを伴ったプロゲステロン受容体拮抗薬の組み合わせ
TWI310685B (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
HK1068098A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20090923

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100930

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100930